Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

A 28-year-old male experiencing early male pattern baldness is considering using Pyrilutamide (KX-826) as an alternative to finasteride due to side effects. He seeks to maintain his current hair without regrowth and is concerned about potential side effects like reduced libido.

KX-826 is a potential hair loss treatment, with users discussing its effectiveness compared to finasteride and concerns about its trial results. Some users express skepticism about new treatments, while others discuss the potential of androgen receptor degraders and the need to manage drug resistance.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

The user is pleased with their hair transplant results after six months and seeks feedback. The conversation is positive, with others affirming the success of the procedure.

The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

The potential hair regrowth benefits of ASC-J9, a synthetic modified version of curcumin that is said to be more effective than Minoxidil and Finasteride. Reports from users suggest good thickening and temple regrowth with topical use at 0.025% concentration.

A user shared their 6-month progress using 1ml of Kirkland minoxidil daily and weekly 1mm dermarolling, noting no side effects and minimal shedding. They plan to consider finasteride or dutasteride after midterms, attributing hair loss to genetics.

A 30-year-old male switched from finasteride to a combination of dutasteride, oral minoxidil, and RU58841, achieving significant hair growth without side effects. He plans to add GHK-Cu peptide to his regimen for further improvement.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

A user shared a 6-month hair loss progress update using a topical solution containing finasteride, minoxidil, ketoconazole, and biotin. They experienced no side effects and found applying the solution with a q-tip more effective than spraying.

A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

A potential baldness cure, possibly PP405, might be available before the release of GTA 6, which is delayed to 2026 or 2027. There is skepticism about the effectiveness and release timeline of PP405.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.

The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.

The conversation is about someone's six-month hair transplant outcome, with a user suggesting the use of finasteride and minoxidil to improve hair growth. Another user commented on the poor condition of the donor hair area.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Finasteride can effectively slow or halt hair loss, even for those genetically predisposed to significant balding, like Norwood 6 or 7. Many users report long-term maintenance or improvement, often combining it with other treatments like Dutasteride or Minoxidil for better results.

The user is using a hair regrowth protocol including dutasteride, topical and oral minoxidil, dermarolling, ketoconazole shampoo, and tretinoin, but is experiencing slow progress and seeks advice for faster regrowth. Suggestions include quitting smoking, adjusting the regimen, and considering additional treatments like topical finasteride or RU58841.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.

The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.